The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 01, 2016

Filed:

Jan. 25, 2013
Applicant:

Ibc Pharmaceuticals, Inc., Morris Plains, NJ (US);

Inventors:

Chien-Hsing Chang, Downingtown, PA (US);

David M. Goldenberg, Mendham, NJ (US);

Donglin Liu, Kendall Park, NJ (US);

Assignee:

IBC Pharmaceuticals, Inc., Morris Plains, NJ (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 47/48 (2006.01); C07K 14/555 (2006.01); C07K 16/00 (2006.01); C07K 16/30 (2006.01); C07K 16/28 (2006.01); C07K 16/46 (2006.01); G01N 33/68 (2006.01); B82Y 30/00 (2011.01);
U.S. Cl.
CPC ...
A61K 39/395 (2013.01); A61K 47/48215 (2013.01); A61K 47/48246 (2013.01); A61K 47/48423 (2013.01); A61K 47/48576 (2013.01); C07K 14/555 (2013.01); C07K 16/00 (2013.01); C07K 16/005 (2013.01); C07K 16/283 (2013.01); C07K 16/3007 (2013.01); C07K 16/468 (2013.01); G01N 33/6866 (2013.01); B82Y 30/00 (2013.01); C07K 2317/31 (2013.01); C07K 2317/55 (2013.01); C07K 2317/73 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C07K 2319/70 (2013.01);
Abstract

The present invention concerns methods and compositions for forming complexes of interferon-λ with an antibody or antigen-binding antibody fragment. In preferred embodiments, the interferon-λ and the antibody or fragment are fusion proteins, each comprising a dimerization and docking domain (DDD) moiety from human protein kinase A or an anchor domain (AD) moiety from an A-kinase anchoring protein (AKAP). In more preferred embodiments, the interferon-antibody complex is more efficacious for treatment of cancer, asthma, Alzheimer's disease, multiple sclerosis or viral infection than interferon-λ alone, antibody alone, or the combination of unconjugated interferon-λ and antibody.


Find Patent Forward Citations

Loading…